Skip directly to content


Academic Eligibility

In 2017 the Wave 2 ASPIRE haemophilia programme is open to investigators from the following countries: Bulgaria, Croatia, Czech Republic, Hungary, Israel, Kyrgyzstan, Mongolia, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey, Ukraine


Optimising care for patients with haemophilia, including but not limited to:

  • Prophylaxis schedules / individualised prophylaxis
  • Pharmacokinetics of factor IX
  • Joint assessment
  • Cost of care
  • Laboratory measurement
  • Patient-reported outcomes

Criteria for Selection

The independent review committee will evaluate all proposals and select those to be awarded grants. Pfizer is not involved in the scientific review process, but will provide communication of the final decisions once available. The independent review committee will not be available to provide any feedback or enter into correspondence with the authors regarding outcome of the award programme. Titles of the awarded projects and names of investigators will be made public through this web page.

Other Funding

No other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the EUROPE ASPIRE programme. However, a EUROPE ASPIRE programme grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the Applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.


For any questions, please email:

May 2017